Disulfiram in APC-mutated Colorectal Cancer Research: Disulfiram's New Role in Precision Oncology

By Editorial Team May 14, 2026

An old drug for alcoholism could transform the way colorectal cancer is treated — from underdog repurposed agent to precision metabolic killer

If you or someone you love has colorectal cancer, this research deserves your attention. A March 2026 preclinical study has uncovered a striking metabolic vulnerability in colorectal cancer cells — one that could transform how an old, inexpensive drug is used against one of the most common cancer mutations in the disease.

The discovery centres on a mutation in the APC gene. Cells carrying this mutation become unusually dependent on an enzyme called ALDH2 to survive. Researchers have been eyeing disulfiram (DSF) as a potential treatment for many cancers for some time — I have been watching it for over ten years. I believe it may help create a cell-death condition similar to ferroptosis called cuproptosis — where copper, rather than iron, is the key trigger (this remains my hypothesis and is speculative at this stage, not established by the 2026 study).

This old, inexpensive drug called disulfiram (DSF), originally used to treat alcohol addiction, strongly inhibits ALDH2, pushing cancer cells into fatal oxidative stress that overwhelms their antioxidant defences. This genetically specific mechanism could transform disulfiram from a broadly promising repurposed drug into a targeted therapy for the large majority of colorectal cancer patients who carry APC mutations. It is a significant finding — and puzzling that it has received so little attention in the national press or mainstream medical reporting.

The APC Mutation: A Major Driver in Colorectal Cancer

Colorectal cancer (CRC) is one of the most common cancers in the world, with nearly 2 million new cases diagnosed each year and an alarming rise in rates among younger patients.

At the heart of many of these tumours is a problem with the APC gene — a natural "brake" on cell growth located on chromosome 5, linked to tumorigenesis. When APC is mutated or lost (which happens in roughly 80–90% of non-inherited colorectal cancers), it causes the Wnt signalling pathway to go into overdrive. There are several repurposed drugs that target this so-called "undruggable" Wnt pathway, but that's a topic for another post.

Wnt pathway dysregulation leads to uncontrolled cell division and elevated reactive oxygen species (ROS) as a by-product. To cope, the cancer cells lean heavily on antioxidant systems — including glutathione and the enzyme ALDH2, which helps neutralise toxic by-products from damaged fats (lipid peroxidation).

New preclinical research published in March 2026 shows that APC-deficient colorectal cancer cells are already living on the metabolic edge because of this extra oxidative burden. They are far more dependent on ALDH2 for survival than normal cells are.

Synthetic Lethality: A Smart Way to Kill Cancer Selectively

This creates what scientists call synthetic lethality — a vulnerability where blocking one thing (ALDH2) is harmless to normal cells but lethal to cells that already carry the APC mutation. It is a two-punch strategy against the cancer cell, and it is one of the most elegant concepts in modern oncology (a topic that deserves its own post).

Disulfiram (DSF) fits the role perfectly. It is an FDA-approved drug, sold as Antabuse, in use since the 1940s. When someone takes it and then drinks alcohol, they experience intense nausea and a severe headache — because it blocks aldehyde dehydrogenase enzymes (ALDH), including ALDH2.

Disulfiram's Long Road from Alcohol Treatment to Cancer Research

For decades, researchers have explored disulfiram's potential against cancer, particularly because many cancer stem cells rely on ALDH enzymes to survive. In colorectal cancer studies prior to 2020, DSF (often combined with copper) demonstrated the ability to kill cancer cells by disrupting the proteasome, inducing cellular stress, and triggering immune responses.

That earlier work was fairly broad — attempting to kill cancer cells without focusing on specific mutations. The 2026 study changes that calculus entirely: it demonstrates that disulfiram is especially effective because it exploits a unique vulnerability created by APC mutations.

How It Actually Works: Overwhelming the Cell with Stress

In lab models using APC-mutant colorectal cancer organoids (miniature tumours grown in a dish) and mouse xenografts, disulfiram dramatically reduced cancer cell survival — often by 50–70% as a single agent, and nearly completely when combined with a small amount of copper.

Here is why: APC-mutant cells already produce excess toxic aldehydes from lipid peroxidation. ALDH2 normally clears these. When disulfiram blocks ALDH2, the toxic aldehydes accumulate, ROS levels spike, and this activates a stress signalling cascade (ASK1 → JNK) that drives the cell into apoptosis — programmed cell death.

In mice bearing APC-mutant tumours, the disulfiram + copper combination shrank tumours by approximately 60% without apparent harm to normal tissues. Cells lacking the APC mutation were largely unaffected, underscoring the selectivity of this approach.

⚠️ Important note: All data cited here is preclinical — from cell models and mouse studies. No head-to-head clinical trials comparing disulfiram to standard treatments have been completed. These findings are promising and mechanistically compelling, but human trial confirmation is the essential next step.

Why This Matters

APC mutations are extremely common in colorectal cancer: they occur in 60–70% of right-sided colon tumours and in nearly all cases of familial adenomatous polyposis (FAP). They can be identified using standard genetic testing (next-generation sequencing, or NGS) or certain pathology stains — no new biomarkers are required.

Disulfiram has important practical advantages:

It is generic and inexpensive — approximately £15–£17 (~$19–$20) per month
It is taken orally as a pill
It carries a long human safety record spanning over 70 years
Side effects are generally mild (mainly nausea or mild peripheral neuropathy), particularly when patients avoid alcohol
It can potentially be combined with standard chemotherapy (such as 5-FU/leucovorin), immunotherapy, intravenous vitamin C, or other metabolic agents

How It Stacks Up Against Current Treatments

Current metastatic colorectal cancer treatments are often expensive, toxic, and not genetically selective. The table below illustrates the contrast — but note that disulfiram figures come from preclinical data only:

FOLFOX: DNA-damaging chemo — ~40–50% response rate, significant neuropathy and low blood counts, costs thousands per month
Targeted drugs (e.g., for BRAF mutations): effective only in small subsets, very expensive
Disulfiram + copper (preclinical data): high activity in APC-mutant models, mild side effects, costs under £50/month.

Disulfiram: A Closer Clinical Profile

For those wanting more technical detail, here is what we know about DSF's pharmacology in the oncology context:

Disulfiram (DSF) is metabolised to diethyldithiocarbamate (DDC), which chelates copper — hence the rationale for co-administration. Its plasma half-life is approximately 10 hours, which means consistent dosing (typically three times daily) is important for sustained effect. Liposomal or copper-DSF (Cu-ET) formulations are currently in development to address this limitation.

Existing Phase I oncology trials — including NCT03323346 in glioma — have confirmed safety at doses up to 640 mg/day, with copper supplementation shown to be feasible. Toxicity is generally mild: nausea and peripheral neuropathy are the most common concerns, and DSF should be avoided in patients who drink alcohol or have Wilson's disease (a copper metabolism disorder).

Potential combination strategies include pairing DSF with 5-FU/leucovorin (standard adjuvant chemotherapy), PD-1 immunotherapy (where DSF's immunogenic cell death effects may be synergistic), metformin (AMPK activation), or statins (mevalonate pathway inhibition) to further amplify oxidative stress in cancer cells.

For patient selection: APC mutation status is detectable via standard NGS panels (such as MSK-IMPACT) or immunohistochemistry (nuclear β-catenin staining). Patients without APC mutations — approximately 10–20% of colorectal cancer cases — would not be expected to benefit from this approach.

Looking Ahead: Time for Clinical Trials

This discovery opens the door for smarter, mutation-guided use of an established drug. The logical next steps are clinical trials specifically enrolling patients with APC-mutant colorectal cancer — testing DSF (with or without copper) added to standard treatment regimens.

Patients and advocates can help move this forward by:

Asking their doctors about APC mutation testing via NGS
Supporting repurposed-drug research and advocacy organisations
Pushing for basket trials that match treatments to specific genetic profiles

In lower-resource settings, an affordable, oral option like disulfiram could make a meaningful difference where expensive biologics remain out of reach.

A Final Word

This ALDH2–APC synthetic lethality finding is mechanistically sound, genetically precise, and clinically actionable. If upcoming trials confirm these results, disulfiram could evolve from a decades-old alcohol-aversion pill into a genuine targeted therapy for the majority of colorectal cancer patients.

It is a clear example of precision metabolic oncology in action — identifying the specific survival dependencies created by a common mutation, and using them as an Achilles' heel. For patients with APC-mutant colorectal cancer, it is a finding worth knowing about and worth discussing with your oncologist.

Let's hope it reaches the national papers.

Share this article if you found it useful. Subscribe for more on metabolic approaches to cancer treatment.

Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice. Disulfiram is not currently approved for cancer treatment. Please consult a qualified oncologist before making any changes to your treatment plan.

Original Article by: Jane McLelland | May 2026

Medically Reviewed by: One Day MD Editorial Team

Search This Blog

Cancer Advisor